

OCTOBER 16-19, 2024
CHICAGO, ILLINOIS



Chicago Specials

Fall Group Meeting

Immunotherapeutics Committee

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 James Moon, MS
 Allison Hayes, BS

Designates

Data Coordinators: Taylor Vlaming
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trial Program Manager: Laura Gildner, MS

Time/Location

Thursday, October 17, 2024 10:45 a.m. - 12:45 p.m.
 Room: Water Tower (Concourse Level, West Tower)

Agenda

10:45 – 10:50 am Welcome & Introductions
 Siwen Hu-Lieskovan & Katerina Politi
 SWOG Immunotherapeutics Committee Co-Chairs

10:50 - 11:05 am RNA Lipid Particle Aggregates in Brain Tumors
 Elias Sayour, MD, PhD
 Associate Professor, Assistant Dean
 Stop Children's Cancer/Bonnie R. Freeman Professor for
 Pediatric Oncology Research

11:05 – 11:15 am Q & A

11:15 – 11:30 am New IO Agents in the CTEP Portfolio
 Helen Chen, MD
 Associate Chief and Senior Investigator
 Cancer Therapy Evaluation Program
 National Cancer Institute
 Brian Ko, MD
 Medical Officer
 Investigational Drug Branch
 Cancer Therapy Evaluation Program

11:30 – 11:40 am Q & A

11:40 – 11:50 am S2013 I-CHECKIT Trial Update
 Krishna Soujanya Gunturu, MD
 Associate Chief, Clinical Trials and Correlative
 Science Research
 Hartford HealthCare Cancer Institute

11:50 – 11:55 am Q & A

11:55 – 12:05 pm SITC's Resistance Data Collection Effort, led by SITC's
 Immunotherapy Resistance Committee
 Megan Othus, PhD
 Professor, Biostatistics and Biomathematics
 Public Health Sciences Division, Fred Hutch

12:05 – 12:10 pm Q & A

12:10 – 12:20 pm S1609 DART Trial Update
 Young Kwang Chae, MD, MPH
 Associate Professor, Medicine
 Hematology Oncology Division
 Northwestern University

12:20 – 12:25 pm Q & A

12:25 – 12:35 pm Alliance Update - IO Committee Efforts & Initiatives
 David E. Kozono, MD, PhD
 Assistant Professor of Radiation Oncology
 Harvard Medical School
 Director, Thoracic Radiation Oncology

12:35 – 12:40 pm Q&A

12:40 – 12:45 pm Final Comments & Closing Remarks
 Siwen Hu-Lieskovan & Katerina Politi
 SWOG Immunotherapeutics Committee Co-Chairs

Active Study

S2101, "Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22.

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

Immunotherapeutics Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

<i>Essentia Health NCI Community Oncology Research Program</i>	1
<i>Froedtert and the Medical College of Wisconsin LAPS</i>	2
<i>Heartland Cancer Research NCORP</i>	1
<i>New Mexico Minority Underserved NCORP</i>	1
<i>Northwestern University LAPS</i>	1
<i>Pacific Cancer Research Consortium NCORP</i>	1
<i>University of Arkansas for Medical Sciences</i>	2
<i>University of Michigan Comprehensive Cancer Center LAPS</i>	12
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	8
<i>ALLIANCE</i>	7
<i>ECOG-ACRIN</i>	6
<i>NRG</i>	5
Total	47

S2101

